LifeMD, a telehealth company promoted by Novo Nordisk, has faced allegations from former employees who claim the firm prioritized profit over patient safety. According to five current and former staff members interviewed by STAT and two lawsuits filed by former senior executives, LifeMD pressured its clinicians to process more patients and issue prescriptions quickly, often without adequate screening or follow-up. The company, which denies the accusations, operates within a broader network of GLP-1 telehealth firms that have gained momentum due to the success of weight-loss medications like Ozempic and Wegovy. LifeMD is part of a growing sector of telehealth services that provide access to GLP-1 drugs, which are used to treat type 2 diabetes and obesity. These services are increasingly popular as newer, more potent versions of such drugs become available. Novo Nordisk, the manufacturer of Ozempic and Wegovy, lists LifeMD on its official website as a trusted partner offering “legitimate medicine sourcing and patient support.” However, insiders paint a different picture, describing the company as one that incentivizes high prescription volumes at the potential cost of medical thoroughness. According to former employees, clinicians were expected to handle up to 25 patient cases per hour, reviewing only electronic forms completed by patients. This equates to approximately two minutes spent per case, raising concerns about the depth of medical evaluation. Some workers stated that they were instructed not to ask what they considered medically necessary questions during consultations, to avoid delaying care. Such practices, if true, suggest a systemic pressure to increase throughput rather than ensure comprehensive care. The situation highlights ongoing challenges in the regulation of telehealth services, particularly those linked to high-stakes medications. Experts warn that the rapid expansion of these services, driven by both pharmaceutical companies and demand for effective treatments, may lead to compromised clinical oversight. With more powerful obesity drugs entering the market, there is concern that inadequate monitoring could result in serious adverse effects among patients. In response to the allegations, LifeMD has issued statements denying the claims, asserting that its operations adhere to all applicable standards and regulations. The company has not publicly commented on specific employee accounts or legal actions brought against it. However, the controversy has sparked wider discussions about the responsibilities of pharmaceutical firms in overseeing the quality of care delivered through affiliated or partnered telehealth platforms. Legal proceedings involving LifeMD include two lawsuits initiated by former top leadership, alleging violations of professional conduct and ethical standards. While the outcomes of these cases remain pending, the allegations underscore a growing scrutiny of how pharmaceutical companies interact with and influence the delivery of healthcare services through third-party providers. As the regulatory landscape continues to evolve, the balance between innovation and accountability will remain a critical focus for policymakers and health professionals alike.
2 izvještaja
STAT NewsNeovisanProgresivnoČinjenice 80Objektivnost 65jučerTelemedicinska tvrtka LifeMD, koja je povezana s Novo Nordiskom, suočena je s optužbama bivših zaposlenika koji tvrde da je tvrtka prioritetirala profit nad sigurnošću pacijenata.
Procjena pristranosti (Progresivno): U članku se pitanje postavlja kroz prizmu korporativnog utjecaja na zdravstvene prakse, naglašavajući zabrinutost zbog profitno vođenih odluka koje utječu na sigurnost pacijenata.
Zašto činjenice (80): The article accurately reflects the claims made by former employees about LifeMD's practices and aligns with the primary source document's emphasis on Novo Nordisk's non-endorsement of providers. It provides specific details about the workload expectations and lack of medical inquiry, which are cons
Zašto objektivnost (65): While the article presents the allegations against LifeMD clearly, it maintains a somewhat critical tone throughout, focusing on the negative aspects of the company's operations. This suggests a slight editorial lean towards highlighting potential risks to patient safety.
STAT NewsNeovisanSredinaČinjenice 75Objektivnost 60jučer STAT+: Pharmalittle: Čitamo o telemedicinskoj tvrtki i sigurnosti pacijenata, prekoračenju PBM-a i još mnogo togaU članku se raspravlja o zabrinutosti oko sigurnosti pacijenata u uslugama telezdravstva koje pruža LifeMD, koji je naveden u Novo Nordisku kao legitimni pružatelj lijekova GLP-1, kao što su Ozempic i Wegovy. Bivši zaposlenici navodno su opisali LifeMD kao da daje prednost količini recepata nad kliničkom odgovornošću, a neki su tvrdili da su pružatelji bili pod pritiskom da obrađuju do 25 slučajeva na sat isključivo na temelju elektroničkih obrazaca pacijenata.
Procjena pristranosti (Sredina): U članku su predstavljene informacije o pitanjima povezanima s praksom zdravstvene zaštite i financijskim upravljanjem u farmaceutskoj industriji, istaknuvši zabrinutost zbog sigurnosti pacijenata i potencijalnog lošeg upravljanja javnim sredstvima.
Zašto činjenice (75): The article references Novo Nordisk's listing of LifeMD as a provider offering 'legitimate medicine sourcing and patient support' and cites former employees' claims about LifeMD prioritizing volume over patient safety. These claims align with the primary source document's disclaimer that Novo Nordis
Zašto objektivnost (60): The article presents the allegations against LifeMD in a critical tone, suggesting a bias toward portraying the company negatively. It frames the situation as a conflict between corporate interests and patient safety, which may reflect a particular perspective rather than presenting both sides equal
★
Neka vijesti ostanu poštene.
ObjectiveNews financiraju čitatelji i bez oglasa je – pristranost vam pokazujemo, ne skrivamo. Podržite neovisno novinarstvo za 5 €/mjesec.
Postani podupiratelj
United States
